Rapamune

Rapamune is a brand name of sirolimus, approved by the FDA in the following formulation(s):

RAPAMUNE (sirolimus - solution; oral)

• 
  Manufacturer: WYETH PHARMS INC
  
  Approval date: September 15, 1999
  
  Strength(s): 1MG/ML ^[RLD]

RAPAMUNE (sirolimus - tablet; oral)

• 
  Manufacturer: WYETH PHARMS INC
  
  Approval date: August 25, 2000
  
  Strength(s): 1MG
  


• 
  Manufacturer: WYETH PHARMS INC
  
  Approval date: August 22, 2002
  
  Strength(s): 2MG ^[RLD]


• 
  Manufacturer: WYETH PHARMS INC
  
  Approval date: January 25, 2010
  
  Strength(s): 0.5MG
  

Has a generic version of Rapamune been approved?

No. There is currently no therapeutically equivalent version of Rapamune available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rapamune. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
  Patent 5,100,899
  Issued: March 31, 1992
  Inventor(s): Calne; Roy
  This invention provides a method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal a transplant rejection inhibiting amount of rapamycin. Also disclosed is a method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal (a) an amount of rapamycin in combination with (b) an amount of one or more other chemotherapeutic agents for inhibiting transplant rejection, e.g., azathioprine, corticosteroids, cyclosporin and FK506, said amounts of (a) and (b) together being effective to inhibit transplant rejection and to maintain inhibition of transplant rejection.
  
  Patent expiration dates:
  
  
  • July 7, 2013
    
    ✓ 
    Patent use: INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
  
  
  
  • January 7, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Surface modified drug nanoparticles
  Patent 5,145,684
  Issued: September 8, 1992
  Inventor(s): Liversidge; Gary G. & Cundy; Kenneth C. & Bishop; John F. & Czekai; David A.
  Assignee(s): Sterling Drug Inc.
  Dispersible particles consisting essentially of a crystalline drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm, methods for the preparation of such particles and dispersions containing the particles. Pharmaceutical compositions containing the particles exhibit unexpected bioavailability and are useful in methods of treating mammals.
  
  Patent expiration dates:
  
  
  • July 25, 2011
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof
  Patent 5,403,833
  Issued: April 4, 1995
  Inventor(s): Calne; Sir Roy
  This invention provides a method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal a transplant rejection inhibiting amount of rapamycin. Also disclosed is a method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal (a) an amount of rapamycin in combination with (b) an amount of one or more other chemotherapeutic agents for inhibiting transplant rejection, e.g., azathioprine, corticosteroids, cyclosporin and FK506, said amounts of (a) and (b) together being effective to inhibit transplant rejection and to maintain inhibition of transplant rejection.
  
  Patent expiration dates:
  
  
  • April 4, 2012
    
    ✓ 
    Patent use: INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
  
  
  
  • October 4, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Rapamycin formulations for oral administration
  Patent 5,536,729
  Issued: July 16, 1996
  Inventor(s): Waranis; Robert P. & Leonard; Thomas W.
  Assignee(s): American Home Products Corporation
  The present invention provides novel oral rapamycin formulations which have, per 100 ml of the formulation, from about 0.01 grams to about 5.0 grams of rapamycin, from about 0.05% to about 10% by volume of surfactant, and from about 75% to about 99.95% by volume of a solution of phospholipid or lecithin in which the phospholipid or lecithin therein is 40% to 75% by weight.
  
  Patent expiration dates:
  
  
  • September 30, 2013
    
    ✓ 
    Drug product
  
  
  
  • March 30, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Rapamycin formulations for oral administration
  Patent 5,989,591
  Issued: November 23, 1999
  Inventor(s): Nagi; Arwinder S.
  Assignee(s): American Home Products Corporation
  This invention provides rapamycin solid dosage unit which comprises a core and a sugar overcoat, said sugar overcoat comprising rapamycin, one or more surface modifying agents, one or more sugars, and optionally one or more binders.
  
  Patent expiration dates:
  
  
  • March 11, 2018
    
    ✓ 
    Drug product
  
  
  
  • September 11, 2018
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Rapamune Consumer Information (Wolters Kluwer)
• Rapamune Solution Consumer Information (Wolters Kluwer)
• Rapamune Consumer Information (Cerner Multum)
• Rapamune Advanced Consumer Information (Micromedex)
• Rapamune AHFS DI Monographs (ASHP)
• Sirolimus Consumer Information (Wolters Kluwer)
• Sirolimus Solution Consumer Information (Wolters Kluwer)
• Sirolimus Consumer Information (Cerner Multum)
• Sirolimus Advanced Consumer Information (Micromedex)
• Sirolimus AHFS DI Monographs (ASHP)